India has invoked its compulsory licensing rules for the first time, allowing the domestic drugmaker Natco Pharma to make and sell a version of Bayer’s cancer drug Nexavar–despite the fact that Nexavar is still on patent.

We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ?

Indian government forces Bayer to accept generic Nexavar competition – FiercePharma.